OncoMab GmbH has entered into a transaction with

 

Patrys Limited, pursuant to which Patrys has

 

acquired from OncoMab rights to human antibody

 

technologies and a pipeline of human anti-cancer

 

antibodies.

 

 

 

Please see the press release and

 

visit www.patrys.com